BN Business News
Add your company to Business Communicator →

Regulation & law · 28/12/2020

National Cancer Institute to Grant Exclusive Patent License to Morphiex for Cancer Treatment

The National Cancer Institute is considering granting an exclusive patent license to Morphiex Biotherapeutics to use a CD47 phosphorodiamidate morpholino oligomer for cancer treatment, prevention, and diagnosis.

Original source language: Federal Register — All DocumentsOpen original release →

Explore insights